Interstitial lung diseases (ILDs) encompass a diverse group of pulmonary conditions characterized by inflammation and fibrosis of the lung interstitium. These diseases pose significant diagnostic and therapeutic challenges due to their complex etiologies, variable clinical presentations, and unpredictable disease courses.
ILDs are classified based on their etiology into idiopathic, connective tissue disease-associated, and exposure-related. Idiopathic pulmonary fibrosis (IPF) is the most common idiopathic ILD, while rheumatoid arthritis is frequently associated with connective tissue disease-related ILD. Exposure to environmental and occupational hazards like asbestos can also cause ILD.
Clinically, ILDs often present with progressive dyspnea, non-productive cough, and bilateral inspiratory crackles. High-resolution computed tomography (HRCT) is the gold standard for diagnosing ILD, with characteristic findings of ground-glass opacities, reticulation, and honeycombing. Additionally, pulmonary function tests show a restrictive pattern with reduced diffusing capacity for carbon monoxide.
Management of ILDs is multifaceted, involving pharmacological and non-pharmacological approaches. Current pharmacological options include antifibrotic agents like pirfenidone and nintedanib, which slow disease progression in IPF. Non-pharmacological strategies involve pulmonary rehabilitation, oxygen therapy, and lung transplantation in advanced cases.
The prognosis of ILD varies widely depending on the specific diagnosis, with a median survival of 2-3 years in IPF. Early diagnosis and appropriate management can significantly improve the quality of life and survival in patients with ILD.
Understanding the complexities of ILDs is crucial for healthcare professionals. A comprehensive approach to diagnosis and management, including awareness of the various etiologies, recognition of clinical manifestations, and knowledge of current treatment options, is essential to optimize patient outcomes in these challenging conditions.
1.
Research discovery halts childhood brain tumor before it forms
2.
Increased Data Support Active Monitoring for Low-Risk Prostate Cancer.
3.
'CDC Must Be Investigated'; David Lynch, Bob Uecker Die; Nasal Epinephrine Warning
4.
Increasing Access to Prostate Cancer Drugs; Reducing Toxic Emissions; FTC Files a 'Charity' Suit.
5.
Infections the Main Cause of Nonrelapse Mortality After CAR-T for Blood Cancers
1.
Beyond the Blinders: A Review of Targeted Therapeutic Strategies for Triple-Negative Breast Cancer in 2025
2.
AI-Based Cancer Follow-Up Monitoring: Transforming Survivorship Care through Intelligent Surveillance
3.
Preventing Sarcopenia During Cancer Treatment
4.
Guidance for Managing Complex Anticoagulation
5.
Unlocking the Potential of Sarclisa: A New Hope for Cancer Treatment
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Updates on Standard V/S High Risk Myeloma Treatment
2.
Navigating the Complexities of Ph Negative ALL - Part XIV
3.
Current Scenario of Blood Cancer- A Conclusion on Genomic Testing & Advancement in Diagnosis and Treatment
4.
Advances in Classification/ Risk Stratification of Plasma Cell Dyscrasias
5.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part I
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation